Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany discusses the need for new drugs in the HER2-positive metastatic space in 2021, as well as the potential clinical benefit of CDK46 inhibitors, AKT inhibitors, and abemaciclib for patients with HER2+, HER3+, and luminal breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).